CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 365-375

  Kim, Hyun Mi ^a,b   Kim, Choung Soo ^a,b   Lee, Je Hwan ^a,b   Jang, Se Jin ^a,b   Hwang, Jung Jin ^a,b   Ro, Seonggu ^c   Hyun, Young Lan ^c   Choi, Jene ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c CrystalGenomics Inc   (South Korea)

Author keywords

Breast cancer; CG0006; HDAC6; Histone deacetylase inhibitor; Hsp90; Tamoxifen

Indexed keywords

ALPHA TUBULIN; CG0006; CHAPERONE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PROCASPASE 9; PROTEIN P21; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CASPASE 9; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERIDINES; PROTEIN BIOSYNTHESIS; PROTEOLYSIS; RECEPTOR, ERBB-2; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 82955234117     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1310-4     Document Type: Article

References (37)

1. Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277:8-21
2. Ma X, Ezzeldin HH, Diasio RB (2009) Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69:1911-1934
3. Balasubramanian S, Verner E, Buggy JJ (2009) Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 280:211-221
4. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6:873-883
5. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-1252 (Pubitemid 350106355)
6. Margueron R, Duong V, Castet A, Cavaillès V (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68:1239-1246 (Pubitemid 39094290)
7. Thomas S, Munster PN (2009) Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 280: 184-191
8. Park WC, Jordan VC (2002) Selective estrogen receptor modu-lators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 8:82-88 (Pubitemid 34094444)
9. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M (2000) Prediction of clinical out-come from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer 6:616-621 (Pubitemid 30111487)
10. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE (2001) Synergistic activation offunctional estrogen receptor (ER)-a by DNA methyltransferase and histone deace-tylase inhibition in human ERa-negative breast cancer cells. Cancer Res 61:7025-7029 (Pubitemid 32946489)
11. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl Cp G binding proteins and histone deacetylase 1 from the estrogen receptor a (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19:1740-1751 (Pubitemid 41007887)
12. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor a (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat 81:177-186 (Pubitemid 37352455)
13. Fortunati N, Bertino S, Costantino L, De Bortoli M, Compagnone A, Bandino A, Catalano MG, Boccuzzi G (2010) Valproic acid restores ERa and antiestrogen sensitivity to ERa-negative breast cancer cells. Mol Cell Endocrinol 314:17-22
14. Reid G, Métivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, Gannon F (2005) Multiple mecha-nisms induce transcriptional silencing of a subset of genes, including oestrogen receptor a, in response to deacetylase inhi-bition by valproic acid and trichostatin A. Oncogene 24:4894-4907 (Pubitemid 41129094)
15. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor a levels and transcriptional activity: a result of hyper-acetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13:4882-4890 (Pubitemid 47294796)
16. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM (2001) The histone deacetylase inhibitor suberoy-lanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497 (Pubitemid 33131130)
17. Margueron R, Licznar A, Lazennec G, Vignon F, Cavaillès V (2003) Oestrogen receptor a increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetyl-ase inhibitors in human breast cancer cells. J Endocrinol 179:41-53 (Pubitemid 37321566)
18. Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T (1999) Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci 886:195-199 (Pubitemid 30042437)
19. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC (2008) Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68:2375-2383
20. Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS (2009) A novel histone deacetylase inhib-itor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. Anticancer Drugs 20:815-821
21. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells\-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-19 (Pubitemid 46976633)
22. Blagg BS, Kerr TD (2005) Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 26:310-338
23. Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Overexpression of cyclin D1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98:415-418 (Pubitemid 34188685)
24. Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P, Thompson AM (2010) High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer 127:355-360
25. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458 (Pubitemid 34563539)
26. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP (2005) HDAC6 regu-lates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601-607 (Pubitemid 40726236)
27. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohl-schlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for post-menopausal early breast cancer: BIG 1-98. J Clin Oncol 25: 3846-3852 (Pubitemid 47477259)
28. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112 (Pubitemid 37328797)
29. Huang L, Pardee AB (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849-866
30. Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G (2008) Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett 259:156-164 (Pubitemid 350251639)
31. Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, Carducci M, Rodriguez R (2006) Chronic administration of val-proic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237-7244 (Pubitemid 44197704)
32. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H (2004) Identification of genes up-regulated by histone deacetylase inhibition with c DNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 41:436-445 (Pubitemid 39158753)
33. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, De Conti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25:1979-1985 (Pubitemid 46972780)
34. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor a-negative breast cancer cells to tamoxifen. Oncogene 23:1724-1736 (Pubitemid 38445164)
35. Sharma D, Saxena NK, Davidson NE, Vertino PM (2006) Res-toration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66:6370-6378
36. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729-26734 (Pubitemid 41040705)
37. Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Miyagi-Maesima A, Matsuno Y, Tobinai K (2010) Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101:196-200